Loading…
South India-focused diagnostics chain (Hyderabad-based) offering pathology and radiology testing services.
South India-focused diagnostics chain (Hyderabad-based) offering pathology and radiology testing services.
Revenue per patient depends on the mix of lab tests and imaging scans, and centres are filled by walk-in patients and doctor referrals. It is based in Hyderabad and listed in 2021.
Moat: narrow (brand, installed base). Strong regional brand and integrated pathology-plus-radiology model in south India.
Headquarters: Hyderabad, India · Founded: 1981 · Employees: 2,507
Size Vijaya Diagnostic Centre (VIJAYA.NS) is an India Health Care company (Medical/Nursing Services) with a market value of $1.60B, the 440th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹1,469 on 6 Nov 2026.
Performance Over six months the shares gained 21.6%, against +17.9% for the median peer and 0.0% for the India market (cap-weighted) — 10th highest of 21 in its peer set.
Growth Revenue grew 24.5% over the last twelve months (peer median +5.9%); the operating margin is 32.1% (peer median 3.2%).
Valuation It trades at 64.3× forward earnings against a peer median of 31.7× (5th most expensive of 16).
Price implies For today's price to make sense, revenue must grow about 39% a year for seven years (Req g). Recent delivered growth is +17%, so the hurdle is +23 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 5.7 points above its cost of capital (12.3% WACC).
Next results Next results expected around 17 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.11B | ₹8.14B | ₹6.81B | ₹5.48B | ₹4.59B |
| Revenue growth | — | +19% | +24% | +19% | — |
| Gross profit | ₹5.65B | ₹4.41B | ₹3.67B | ₹2.94B | ₹2.25B |
| EBITDA | ₹3.93B | ₹3.40B | ₹2.76B | ₹2.23B | ₹1.84B |
| Net income | ₹2.04B | ₹1.73B | ₹1.44B | ₹1.19B | ₹846M |
| Free cash flow | n/a | ₹636M | ₹1.08B | ₹1.03B | ₹461M |
| Capital expenditure | n/a | ₹1.83B | ₹956M | ₹880M | ₹1.25B |
| Total debt | ₹5.09B | ₹4.23B | ₹3.20B | ₹2.59B | ₹2.48B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vijaya Diagnostic Centre VIJAYA.NS | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% |
| Dr. Lal PathLabs LALPATHLAB.NS | $3.50B | +26% | +17% | 24% | 51.5× | 32.2% |
| Metropolis Healthcare METROPOLIS.NS | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIJAYA.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.4% | +7.8% | 7th lowest of 21 |
| 6-month return | +21.6% | +17.9% | 10th highest of 21 |
| Distance from 52-week high | -7.8% | -17.1% | 6th highest of 21 |
| Revenue growth (TTM) | +24.5% | +5.9% | 4th highest of 21 |
| Operating margin | 32.1% | 3.2% | highest of 21 |
| Forward P/E | 64.3× | 31.7× | 5th most expensive of 16 |
| Growth the price implies (Req g, 7 yrs) | 39.3% | 12.6% | 3rd most demanding of 15 |
| Growth delivered (Del g) | +16.7% | +8.7% | 5th highest of 15 |
| Hurdle (Req g minus delivered) | +22.6 pp | +7.4 pp | 2nd most demanding of 15 |
| ROIC minus cost of capital | +5.7 pp | -4.1 pp | 2nd highest of 20 |
| EV / EBITDA | 38.9× | 21.1× | 2nd most expensive of 14 |
| Net debt / EBITDA | 0.4× | 2.8× | 4th least indebted of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vijaya Diagnostic Centre VIJAYA.NS | India | $1.60B | +22% | +24% | 32% | 64.3× | 39.3% | +16.7% |
| Teladoc Health TDOC | United States | $1.60B | +21% | -2% | -5% | n/a | -5.2% | +18.3% |
| Sonida Senior Living SNDA | United States | $1.58B | -14% | +49% | -11% | n/a | n/a | n/a |
| Ambea AMBEA.ST | Sweden | $1.63B | +30% | +13% | 8% | 15.8× | 1.7% | +7.7% |
| Ping An Healthcare and Technology 1833.HK | Hong Kong | $1.63B | -47% | +8% | 3% | 40.1× | 15.0% | -5.1% |
| Personalis PSNL | United States | $1.71B | +164% | -13% | -164% | n/a | n/a | n/a |
| Azenta AZTA | United States | $1.72B | +104% | +1% | -3% | 103.7× | 56.0% | +8.9% |
| U.S. Physical Therapy USPH | United States | $1.48B | +68% | +11% | 10% | 30.4× | 19.9% | +13.0% |
| Dr. Agarwal's Health Care AGARWALEYE.NS | India | $1.74B | +15% | +22% | 15% | 89.1× | 41.9% | +26.9% |
| Clariane CLARI.PA | France | $1.40B | -20% | +1% | 6% | 8.6× | 6.7% | +6.5% |
| GeneDx WGS | United States | $1.86B | +53% | +25% | -12% | 98.7× | n/a | n/a |
| H.U.Group 4544.T | Japan | $1.35B | +24% | +1% | 2% | 41.0× | 10.1% | +2.1% |
| agilon health AGL | United States | $1.90B | +109% | 0% | -4% | 67.5× | n/a | n/a |
| Emeis EMEIS.PA | France | $1.94B | -30% | +4% | 3% | n/a | 21.3% | +8.5% |
| Dian Diagnostics 300244.SZ | China | $1.97B | +11% | -5% | 9% | 25.2× | 2.4% | -1.1% |
| Diagnostyka DIA.WA | Poland | $1.29B | -5% | +19% | 15% | 18.4× | 6.9% | +18.9% |
| OPKO Health OPK | United States | $1.29B | +52% | -11% | -29% | n/a | n/a | n/a |
| Lumexa Imaging LMRI | United States | $1.29B | +29% | +8% | 3% | 18.6× | n/a | n/a |
| Guangzhou Kingmed Diagnostics 603882.SS | China | $1.99B | +5% | -3% | 7% | 31.7× | 6.7% | -6.1% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |